Venöz Ülser Tedavisinde Venoaktif İlaçlar

Yıl 2017, Cilt: 12 Sayı: 3, 19 - 21, 11.12.2017

Alptekin Yasım

https://doi.org/10.17517/ksutfd.351614

Öz

Venöz ülserler anlamlı morbiditeye
sebep olan önemli tıbbi sorunlardır.  Primer
venöz yetmezliğin ileri evrelerinde veya venöz yetmezliğe bağlı oluşan posttrombotik
sendrom sonucunda gelişir. Tedavisi kompresyon, bacak elevasyonu, local yara
bakımı, ilaç tedavisi ve altta yatan venöz patolojinin cerrahi veya girişimsel
olarak düzeltilmesidir. Diğer tedavi yöntemleri eğer kompresyon tedavisi ile
birlikte uygulanırsa başarılı olabilir. Biz burada venöz ülser tedavisinde
venoaktif ilaçların etkinliğini bilimsel kanıtlar eşliğinde tartıştık.

Anahtar Kelimeler

venöz ülser, venoaktif ilaç, venöz yetmezlik

VENOACTIVE DRUG THERAPY ON TREATMENT OF VENOUS ULCER

Öz

Venous ulcers are important medical
problem that caused significant morbidity. They develop as a result of advanced
chronic venous insufficiency, caused most frequently by primary venous
incompetence or the post thrombotic syndrome. Treatment of venous ulcers
include compression therapy, leg elevation, local ulcer and skin care, drug
treatment, and correction of the underlying venous pathology with surgical and
endovenous interventions. Primary and sine qua non method to cure venous ulcer
is compression treatment. Other treatment modalities can be successful if only
they have performed with compression treatment. 
In here we discuss the scientific evidence on efficacy of venoactive
drug therapy on treatment of venous ulcer.

Anahtar Kelimeler

Venous ulcer, venoactive drug, venous insufficiency

Kaynakça

• 1. Gloviczki P, Gloviczki ML. Evidence on efficacy of treatments of venous ulcers and on prevention of ulcer recurrence. Perspect Vasc Surg Endovasc Ther 2009; 21: 259-68
• 2. Etufugh CN, Phillips TJ. Venous ulcers. Clin Dermatol 2007; 25: 121-30
• 3. Nicolaides AN, Allegra C, Bergan J. Management of chronic venous disorders of the lower limbs: guidelines according to scientific evidence. Int Angiol 2008; 27: 1-59
• 4. Abbade LP, Lastoria S. Venous ulcer: epidemiology, physiopathology, diagnosis and treatment. Int J Dermatol 2005; 44: 449-56
• 5. Raffetto JD, Marston WA. Venous ulcer: what is new? Plast Reconstr Surg 2010; 127 (Suppl 1): 279S-288S
• 6. Olivencia JA. Pathophysiology of venous ulcers: surgical implication, review and update. Dermatol Surg 1999; 25: 880-5
• 7. Coleridge-Smith P, Thomas P, Scurr JH, Dormandy JA. Causes of venous ulceration: a new hypothesis. Br Med J 1988; 296: 1726–1727
• 8. Claudy AL, Mirshahi M, Soria C, et al. Detection of undegraded fibrin and tumor necrosis factor alpha in venous leg ulcers. J Am Acad Derm 1991; 25: 623–627
• 9. Powell CC, Rohrer MJ, Barnard MR, Peyton BD, Furman MI, Michelson AD. Chronic venous insufficiency is associated with increased platelet and monocyte activation and aggregation. J Vasc Surg 1999; 30: 844–851.
• 10. De Sanctis MT, Belcaro G, Cesarano MR, Ippolito E, Nicolaides AN, Incandela L, et al. Treatment of venous ulcers with pentoxifylline: a 12-month, double-blind, placebo controlled trial. Microcirculation and healing. Angiology 2002; 53 (Suppl 1): S49-S51
• 11. Falanga V, Fujitani RM, Diaz C, Hunter G, Jorizzo J, Lawrence PF, et al. Systemic treatment of venous leg ulcers with high doses of pentoxifylline: efficacy in a randomized, placebo-controlled trial. Wound Repair Regen. 1999; 7: 208-13
• 12. Dale JJ, Ruckley CV, Harper DR, Gibson B, Nelson EA, Prescott RJ. Randomized, double blind placebo controlled trial of pentoxifylline in the treatment of venous leg ulcers. BMJ. 1999 2; 319: 875-8
• 13. Ferrara F, Meli F, Raimondi F, Amato C, Bonura F, Mulè G, et al. The treatment of venous leg ulcers: a new therapeutic use of iloprost. Ann Surg 2007; 246: 860-5
• 14. Layton AM, Ibbotson SH, Davies JA, Goodfield MJ. Randomized trial of oral aspirin for chrinic venous leg ulcers. Lancet 1994; 344: 164-5
• 15. Milio G, Mina C, Cospite V, Almasio PL, Novo S. Efficacy of the treatment with prostaglandin E-1 in venous ulcers of the lower limbs. J Vasc Surg 2005;42:304-8.
• 16. Werner-Schlenzka H, Kuhlmann RK. Treatment of venous leg ulcersvwith topical iloprost: a placebo controlled study. VASA 1994; 23:145- 50
• 17. Coccheri S, Scondotto G, Agnelli G, Aloisi D, Palazzini E, Zamboni V. Randomised, double blind, multicentre, placebo controlled study of sulodexide in the treatment of venous leg ulcers. Thromb Haemost 2002;87:947-52.
• 18. Gohel MS, Davies AH. Pharmacological agents in the treatment of venous disease: An update of the available evidence. Curr Vasc Pharmacol 2009; 7: 303-8
• 19. Perrin M, Ramelet AA. Pharmacological treatment of primary chronic venous disease: Rationale, results and unanswered questions. Eur J Vasc Endovasc Surg 2011; 41: 117-25
• 20. Boisseau MR. Pharmacological targets of grugs employed in chronic venous and lymphatic insufficiency. Int Angiol 2002; 21: 33-9
• 21. Ramelet AA, Boisseau MR, Allegra C, Nicolaides A, Jaeger K, Carpentier P, et al. Veno-active drugs in the management of chronic venous disease. An international consensus statement: current medical position, nprospective views and final resolution. Clin Hemorheol Microcirc 2005; 33: 309-19
• 22. Gloviczki P, Comerota AJ, Dalsing MC, Eklof BG, Gillespie DL, Gloviczki ML, et al. The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg. 2011; 53 (5 Suppl): 2S-48S.
• 23. Wright DD, Franks PJ, Blair SD, Backhouse CM, Moffatt C, McCollum CN. Oxerutins in the prevention of recurrence in chronic venous ulceration: randomized controlled trial. Br J Surg 1991; 78: 1269-70
• 24. Douglas WS, Simpson NB. Guidelines fort he management of chronic venous leg ulceration. Report of a multidisciplinary workshop. Br J Dermatol 1995; 132: 446-52
• 25. Guilhou JJ, Dereure o, Marzin L, Ouvry P, Zuccarelli F, Debure C, et al. Efficacy of Daflon 500 mg in venous leg ulcer healing: a double-blind, randomized, controlled versus placebo trial in 107 patients. Angiology 1997; 48: 77-85
• 26. Glinski W, Chodynicka B, Roszkiewicz J, Bogdanowski T, Lecewicz-Torun B, Kaszuba A, et al. Effectiveness of a micronized purified flavonoid fraction (MPFF) in the healing process of lower limb ulcers. An open multicentre study, controlled and randomized. Minerva Cardioangiol 2001; 49: 107-14
• 27. Roztocil K, Stvrtinova V, Strejcek J. Efficacy of a 6-month treatment with Daflon 500 mg in patients with venous leg ulcers associated with chronic venous insufficiency. Int Angiol 2003; 22: 24-31
• 28. Coleridge-Smith P, Lok C, Ramelet AA. Venous leg ulcer: a meta-analysis of adjunctive therapy with micronized purified flavonoid fraction. Eur J Vasc Endovasc Surg 2005; 30: 198-208
• 29. Robson MC, Cooper DM, Alsam R. Guidelines for the treatment of venous ulcers. Wound Rep Reg 2006; 14: 649-62
• 30. Kaur C, Sarkar R, Kanwar AJ, Attri AK, Dabra AK, Kochhar S. An open trial of calcium dobesilate in patients with venous ulcers and stasis dermatitis. Int J Dermatol 2003; 42: 147-52
• 31. Leach MJ, Pincombe J, Foster G. Clinical efficacy of horsechestnut seed extract in the treatment of venous ulceration. J Wound Care 2006; 15: 159-67
• 32. Moneta GL, Partsch H. Compression therapy for venous ulceration. In: Gloviczki P, ed. Handbook of Venous Disorders . 3rd ed. London, UK: Hodder Arnold; 2009:348-358